Blogs

Previous Blogs

Bucci - The right CCS from the start

By Anthony Bucci Ph.D.

September 02, 2021

Have you ever faced the need to identify a primary package for your drug product, but do not know where to start? Are you faced with tight timelines and component data constraints when evaluating stoppers, seals, and vials for container closure systems (CCS)? Do you need the right data for regulatory filing to support the choice of CCS for your drug product?

Vials Stoppers and Seals

By Abbey Hisler

March 10, 2021

Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market1. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.

By Your Side for Innovation

By Karen Flynn

October 23, 2019

Injectable drug delivery and containment can be a challenge for drug manufacturers, especially as regulations and quality standards are increasing and as biologic drug products present new challenges in their sensitivity and dose volume. At West, we work closely with our customers to understand industry trends, the challenges our customers face, and we work by their side to drive new innovations to support their work to deliver medicines to the patients that need them.